115 related articles for article (PubMed ID: 27388616)
1. Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML.
Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
J Investig Med; 2016 Dec; 64(8):1252-1260. PubMed ID: 27388616
[TBL] [Abstract][Full Text] [Related]
2. Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.
Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
Eur J Haematol; 2016 Dec; 97(6):517-527. PubMed ID: 27096305
[TBL] [Abstract][Full Text] [Related]
3. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
5. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
7. Death Receptor Expression on Blasts in AML Is Associated with Unfavorable Prognosis.
Schmohl JU; Nuebling T; Wild J; Jung J; Kroell T; Kanz L; Salih HR; Schmetzer H
Anticancer Res; 2015 Jul; 35(7):4043-52. PubMed ID: 26124353
[TBL] [Abstract][Full Text] [Related]
8. Sjögren's syndrome-like autoimmune sialadenitis in MRL-Faslpr mice is associated with expression of glucocorticoid-induced TNF receptor-related protein (GITR) ligand and 4-1BB ligand.
Saito K; Mori S; Date F; Ono M
Autoimmunity; 2013 Jun; 46(4):231-7. PubMed ID: 23301790
[TBL] [Abstract][Full Text] [Related]
9. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
[TBL] [Abstract][Full Text] [Related]
10. Podocalyxin is expressed in normal and leukemic monocytes.
Riccioni R; Calzolari A; Biffoni M; Senese M; Riti V; Petrucci E; Pasquini L; Cedrone M; Lo-Coco F; Diverio D; Foà R; Peschle C; Testa U
Blood Cells Mol Dis; 2006; 37(3):218-25. PubMed ID: 17059890
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
12. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis.
Graf M; Reif S; Kröll T; Hecht K; Nuessler V; Schmetzer H
Am J Hematol; 2006 Apr; 81(4):227-35. PubMed ID: 16550517
[TBL] [Abstract][Full Text] [Related]
13. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans.
Baessler T; Krusch M; Schmiedel BJ; Kloss M; Baltz KM; Wacker A; Schmetzer HM; Salih HR
Cancer Res; 2009 Feb; 69(3):1037-45. PubMed ID: 19155305
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.
Liersch R; Gerss J; Schliemann C; Bayer M; Schwöppe C; Biermann C; Appelmann I; Kessler T; Löwenberg B; Büchner T; Hiddemann W; Müller-Tidow C; Berdel WE; Mesters R
Blood; 2012 May; 119(22):5215-20. PubMed ID: 22510874
[TBL] [Abstract][Full Text] [Related]
16. Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.
Vire B; de Walque S; Restouin A; Olive D; Van Lint C; Collette Y
PLoS One; 2009 Sep; 4(9):e7085. PubMed ID: 19759901
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the human 4-1BB/4-1BBL complex.
Gilbreth RN; Oganesyan VY; Amdouni H; Novarra S; Grinberg L; Barnes A; Baca M
J Biol Chem; 2018 Jun; 293(25):9880-9891. PubMed ID: 29720399
[TBL] [Abstract][Full Text] [Related]
18. CD97 is a critical regulator of acute myeloid leukemia stem cell function.
Martin GH; Roy N; Chakraborty S; Desrichard A; Chung SS; Woolthuis CM; Hu W; Berezniuk I; Garrett-Bakelman FE; Hamann J; Devlin SM; Chan TA; Park CY
J Exp Med; 2019 Oct; 216(10):2362-2377. PubMed ID: 31371381
[TBL] [Abstract][Full Text] [Related]
19. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
[TBL] [Abstract][Full Text] [Related]
20. Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.
Hömme C; Krug U; Tidow N; Schulte B; Kühler G; Serve H; Bürger H; Berdel WE; Dugas M; Heinecke A; Büchner T; Koschmieder S; Müller-Tidow C
Oncol Rep; 2010 Jul; 24(1):47-56. PubMed ID: 20514443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
